Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer’s disease dementia in Chinese individuals

Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer’s disease dementia in Chinese individuals

BackgroundPlasma-derived β-amyloid, tau, and neurodegeneration (ATN) biomarkers can accurately diagnose Alzheimer’s disease (AD) and predict its progression. Few studies have investigated the relationship between plasma biomarkers and changes in plasma inflammatory markers in clinically diagnosed AD...

Full description

Bibliographic Details
Main Authors:	Qingling Sun, Jingnian Ni, Mingqing Wei, Siwei Long, Ting Li, Dongsheng Fan, Tao Lu, Jing Shi, Jinzhou Tian
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Aging Neuroscience
Subjects:	Alzheimer’s disease plasma biomarkers inflammatory factors ATN Simoa
Online Access:	https://www.frontiersin.org/articles/10.3389/fnagi.2022.963845/full

Similar Items

Impact of diabetes on the progression of Alzheimer’s disease via trajectories of amyloid–tau–neurodegeneration (ATN) biomarkers
by: Eun Woo Kim, et al.
Published: (2025-02-01)

Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort
by: Christophe Hirtz, et al.
Published: (2023-02-01)

Fully synthetic phosphorylated Tau181, Tau217, and Tau231 calibrators for Alzheimer’s disease diagnosis
by: Xinyu Li, et al.
Published: (2024-01-01)

Diagnostic and predictive power of plasma proteins in Alzheimer's disease: a cross-sectional and longitudinal study in China
by: Wei Li, et al.
Published: (2024-07-01)

SIMOA Diagnostics on Alzheimer’s Disease and Frontotemporal Dementia
by: Athanasia Chatziefstathiou, et al.
Published: (2024-06-01)

Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders
by: Mélina Régy, et al.
Published: (2023-04-01)

Editorial: Genetics and biomarkers of Alzheimer's disease in Asian populations
by: Xiaopu Zhou, et al.
Published: (2024-01-01)

Head-to-Head Comparison of Different Blood Collecting Tubes for Quantification of Alzheimer’s Disease Biomarkers in Plasma
by: Lijun Jiang, et al.
Published: (2022-08-01)

Clinical characteristics of patients with suspected Alzheimer’s disease within a CSF Aß-ratio grey zone
by: Dariia Yosypyshyn, et al.
Published: (2023-08-01)

Risk of dementia in APOE ε4 carriers is mitigated by a polygenic risk score
by: Jarith L. Ebenau, et al.
Published: (2021-01-01)

Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints
by: Jiaying Lu, et al.
Published: (2023-06-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-05-01)

Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease
by: Xiaoling Wang, et al.
Published: (2024-04-01)

Differentiation of Alzheimer's disease from other neurodegenerative disorders using chemiluminescence immunoassays measuring cerebrospinal fluid biomarkers
by: Philipp Arendt, et al.
Published: (2024-10-01)

Corrigendum: Differentiation of Alzheimer's disease from other neurodegenerative disorders using chemiluminescence immunoassays measuring cerebrospinal fluid biomarkers
by: Philipp Arendt, et al.
Published: (2025-02-01)

Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies
by: Agathe Vrillon, et al.
Published: (2024-07-01)

Detecting Early Cognitive Decline in Alzheimer’s Disease with Brain Synaptic Structural and Functional Evaluation
by: Samo Ribarič
Published: (2023-01-01)

Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer’s disease
by: Georgette Argiris, et al.
Published: (2024-12-01)

Exploring the ATN classification system using brain morphology
by: Nils Heinzinger, et al.
Published: (2023-03-01)

Implication of tau propagation on neurodegeneration in Alzheimer’s disease
by: Daniel Lamontagne-Kam, et al.
Published: (2023-07-01)

Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer’s disease
by: Zhengshi Yang, et al.
Published: (2023-11-01)

INTEGRACE ATN SLUŽEB NA DRUŽICOVÝ SYSTÉM
by: Rudolf Volner, et al.
Published: (2010-04-01)

Exploring small non-coding RNAs as blood-based biomarkers to predict Alzheimer’s disease
by: Laia Gutierrez-Tordera, et al.
Published: (2024-01-01)

Ultra-highly sensitive cardiac troponin I: Age and sex differences in healthy individuals
by: Mitra Mastali, et al.
Published: (2022-01-01)

Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease
by: Javier Arranz, et al.
Published: (2024-06-01)

Recent Computational Advances Regarding Amyloid-β and Tau Membrane Interactions in Alzheimer’s Disease
by: Phuong H. Nguyen, et al.
Published: (2023-10-01)

Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer’s disease
by: Yue Cai, et al.
Published: (2023-02-01)

Neuroimaging correlates of Stages of Objective Memory Impairment (SOMI) system
by: Ellen Grober, et al.
Published: (2021-01-01)

Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease
by: Yara Mashal, et al.
Published: (2022-07-01)

Correlation Between Brain Structure Atrophy and Plasma Amyloid-β and Phosphorylated Tau in Patients With Alzheimer’s Disease and Amnestic Mild Cognitive Impairment Explored by Surface-Based Morphometry
by: Kaidi Li, et al.
Published: (2022-04-01)

The global Alzheimer's Association round robin study on plasma amyloid β methods
by: Josef Pannee, et al.
Published: (2021-01-01)

Identifying longitudinal cognitive resilience from cross-sectional amyloid, tau, and neurodegeneration
by: Rory Boyle, et al.
Published: (2024-07-01)

Novel Alzheimer risk genes determine the microglia response to amyloid‐β but not to TAU pathology
by: Annerieke Sierksma, et al.
Published: (2020-01-01)

Microglia activation linking amyloid-β drive tau spatial propagation in Alzheimer's disease
by: Qing Wang, et al.
Published: (2022-08-01)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
by: Rik Ossenkoppele, et al.
Published: (2021-07-01)

Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
by: Juan Lantero-Rodriguez, et al.
Published: (2024-02-01)

Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer’s disease
by: Min Seok Baek, et al.
Published: (2020-10-01)

Overview of the Molecular Modalities and Signaling Pathways Intersecting with β-Amyloid and Tau Protein in Alzheimer’s Disease
by: Ahmed M. Elshazly, et al.
Published: (2023-07-01)

The Roles of Lipid and Glucose Metabolism in Modulation of β-Amyloid, Tau, and Neurodegeneration in the Pathogenesis of Alzheimer disease
by: Naoyuki eSato, et al.
Published: (2015-10-01)

Peripheral Blood and Cerebrospinal Fluid Levels of YKL-40 in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
by: Yuchen Zhang, et al.
Published: (2023-09-01)